Announced Tue, 27 Oct, 2026 · 20:21 IST
Revenue grows 25% in Q2 and 26% in H1, but margins fall
Mgmt Guided Margin PressureOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction
Awaiting price reaction for this filing.
AI summary
Revenue rose 25% to Rs 309.1 crore in Q2 FY27 and 26% to Rs 566.6 crore in H1. Net profit rose 10% to Rs 69.6 crore in Q2 and 19% to Rs 127.3 crore in H1. Gross margin fell to 76.2% from 80.2% on higher input costs and product mix. Concord launched dermatology unit Inspira, received two US generic approvals and has over 10 pipeline products, targeting 2 to 3 launches a year. It also approved a one-for-one bonus issue.
Likely market impact
Strong growth supports optimism, but margin pressure may limit earnings gains. The one-for-one bonus issue increases share count without adding cash.